Safeguarding your patients at risk of VTE
Venous thromboembolism (VTE) is a life-threatening condition affecting 10 million people every year1, with 60% of the cases occurring during or shortly after a hospital stay.2
While healthcare facilities are aware of the risk of VTE, care providers may lack the time, training and resources to optimally implement prevention strategies. In order to safeguard the well-being of at-risk patients, comprehensive prevention strategies that take into account individual clinical needs are essential.
We invite you below to learn about some of the many advantages of IPC and Flowtron ACS900.
Book a demonstration
Book a demo to see, hear and feel the benefits of
Flowtron ACS900 with a personalised demonstration from an Arjo representative.
Key clinical evidence supporting the use of IPC
This clinical resource provides examples of some of the key evidence supporting the use of IPC and specifically the Flowtron Active Compression System as part of a VTE prevention protocol.
Request a training
Are you ready to take the next step and familiarise yourself with IPC therapy using Flowtron ACS900?